Phase II study of BI456906 patients with T2DM Obes
Research payments
$1,878,693
Through program year 2022, $1,878,693 in research payments was reported against Phase II study of BI456906 patients with T2DM Obes, across 32 payments, paid by Boehringer Ingelheim Pharmaceuticals, Inc..
- Paid by
- Boehringer Ingelheim Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $223,470 | 7 |
| 2021 | Research | $1,591,844 | 14 |
| 2020 | Research | $63,379 | 11 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jose Cardona Hialeah, FL Named on 7 payments
- Kathryn Lucas Morehead City, NC Named on 5 payments
- James Andersen Lakeland, FL Named on 4 payments
- Masoud Azizad Northridge, CA Named on 4 payments
- Zaid Jabbar Oak Brook, IL Named on 3 payments
- Bernard Grunstra Bristol, TN Named on 3 payments
- Idalia Acosta Miami Lakes, FL Named on 2 payments
- Yoko Momoyama Oak Brook, IL Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.